Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Mecasermin

EU orphan designation number: EU/3/06/373   
Active ingredient: Mecasermin
Indication: Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects
Sponsor: Ipsen Pharma
65 quai Georges Gorse, F-92100 Boulogne-Billancourt, France
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name INCRELEX on 03/08/2007 with the number EU/1/07/402

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
24/05/2006 Centralised Orphan - Designation EMEA/OD/104/05 (2006)2143 of 22/05/2006
05/07/2007 Other procedure
30/07/2009 Centralised Orphan - Transfer of orphan designation EMEA/OD/104/05/T/01 (2009)6036 of 24/07/2009